lenalidomide has been researched along with Acute Febrile Neutrophilic Dermatosis in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nohgawa, M; Oka, S; Ono, K | 1 |
Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M | 1 |
Kist, JM; Rosenbach, M; Thieu, KP; Xu, X | 1 |
Giorgadze, T; Tageja, N; Zonder, J | 1 |
Davis, MD; Hoverson, AR; Weenig, RH; Wolanskyj, AP | 1 |
5 other study(ies) available for lenalidomide and Acute Febrile Neutrophilic Dermatosis
Article | Year |
---|---|
Ixazomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Sweet Syndrome | 2019 |
Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide.
Topics: Aged; Blood Cell Count; Bone Marrow; Drug Therapy, Combination; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nitrosourea Compounds; Skin; Sweet Syndrome; Thalidomide; Thrombocythemia, Essential; Treatment Outcome | 2014 |
Neutrophilic dermatosis complicating lenalidomide therapy.
Topics: Antineoplastic Agents; Biopsy; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Skin; Sweet Syndrome; Thalidomide | 2009 |
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.
Topics: Erythema; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Sweet Syndrome; Thalidomide | 2011 |
Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide.
Topics: Aged; Diagnosis, Differential; Hand Dermatoses; Humans; Immunologic Factors; Lenalidomide; Male; Primary Myelofibrosis; Sweet Syndrome; Thalidomide | 2006 |